Genetic Tumor Risk Syndromes: Current Aspects of Diagnosis and Genetic Counseling
DOI:
https://doi.org/10.14748/myc3na25Keywords:
genetic tumor risk syndromes, oncogenetics, genetic counseling, NGS, molecular diagnostics, prevention, ethical aspectsAbstract
Genetic tumor risk syndromes (GTRS) account for a significant proportion of oncological diseases, characterized by an increased risk of developing cancer, often at a young age. Modern methods of genomic diagnostics, particularly next-generation sequencing (NGS), have contributed to a revolutionary advance in understanding the underlying molecular mechanisms of these syndromes. Identifying pathogenic variants in genes associated with GTRS is essential for early diagnosis, risk assessment, personalized treatment selection, and the implementation of effective preventive measures. This article provides an overview of the current aspects of GTRS, focusing on some syndromes, their clinical presentation, genetic etiology and molecular mechanisms. It discusses modern diagnostic methods, the role of genetic counseling, and the ethical and psychosocial aspects related to genetic testing. The main guidelines for prevention and follow-up in individuals with GTRS are also outlined, according to the recommendations of leading international organizations. In conclusion, the importance of a multidisciplinary approach in the management of these syndromes and the application of new technologies for risk assessment and personalization of therapeutic approaches are emphasized.
References
[1] Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505(7483):302-8. doi: 10.1038/nature12981. DOI: https://doi.org/10.1038/nature12981
[2] WCT: Genetic Tumour Syndromes [Internet]. Iarc.fr. 2025. Available from: https://whobluebooks.iarc.fr/structures/genetic-tumour-syndromes/
[3] Giancarlo. RARECARENet - Data Source and Methods [Internet]. Istitutotumori.mi.it. 2024 [cited 2024 Dec 17]. Available from: http://rarecarenet.istitutotumori.mi.it/
[4] Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-16. doi: 10.1001/jama.2017.7112. DOI: https://doi.org/10.1001/jama.2017.7112
[5] Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87-99. doi: 10.1016/j.breast.2015.12.010. DOI: https://doi.org/10.1016/j.breast.2015.12.010
[6] Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42(5):584-604. doi: 10.1200/JCO.23.02225. DOI: https://doi.org/10.1200/JCO.23.02225
[7] Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023 Jan;34(1):33-47. doi: 10.1016/j.annonc.2022.10.004. DOI: https://doi.org/10.1016/j.annonc.2022.10.004
[8] Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(5):331-57. doi: 10.6004/jnccn.2024.0035. DOI: https://doi.org/10.6004/jnccn.2024.0035
[9] Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015;15(3):181-94. doi: 10.1038/nrc3878. DOI: https://doi.org/10.1038/nrc3878
[10] Peltomaki P, Nystrom M, Mecklin JP, Seppala TT. Lynch Syndrome Genetics and Clinical Implications. Gastroenterology. 2023;164(5):783-99. doi: 10.1053/j.gastro.2022.08.058. DOI: https://doi.org/10.1053/j.gastro.2022.08.058
[11] Yurgelun MB, Hampel H. Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention. Am Soc Clin Oncol Educ Book. 2018;38:101-9. doi: 10.1200/EDBK_208341. DOI: https://doi.org/10.1200/EDBK_208341
[12] Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, et al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Oct 1;30(10):1558-71. doi: 10.1093/annonc/mdz233. DOI: https://doi.org/10.1093/annonc/mdz233
[13] Hodan R, Gupta S, Weiss JM, Axell L, Burke CA, Chen LM, et al. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2024;22(10):695-711. doi: 10.6004/jnccn.2024.0061. DOI: https://doi.org/10.6004/jnccn.2024.0061
[14] Polyposis syndromes (genturis.eu) [Internet]. Genturis.eu. 2024. Available from: https://www.genturis.eu/l=eng/thematic-disease-groups/lynch-syndrome-and-polyposis/polyposis-syndromes.html
[15] Stoffel EM, Mangu PB, Limburg PJ; American Society of Clinical Oncology; European Society for Medical Oncology. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. J Oncol Pract. 2015 May;11(3):e437-41. doi: 10.1200/JOP.2015.003665. DOI: https://doi.org/10.1200/JOP.2015.003665
[16] Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG; European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020 Oct;28(10):1379-86. doi: 10.1038/s41431-020-0638-4. DOI: https://doi.org/10.1038/s41431-020-0638-4
[17] Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C, Frebourg T. Germline TP53 Testing in Breast Cancers: Why, When and How? Cancers (Basel). 2020 Dec 14;12(12):3762. doi: 10.3390/cancers12123762. DOI: https://doi.org/10.3390/cancers12123762
[18] Garrett A, Callaway A, Durkie M, Cubuk C, Alikian M, Burghel GJ, et al. Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. J Med Genet. 2020;57(12):829-34. doi: 10.1136/jmedgenet-2019-106759. DOI: https://doi.org/10.1136/jmedgenet-2019-106759
[19] Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al. NCCN Guidelines(R) Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024;22(1):4-16.
[20] Lalloo F, Kulkarni A, Chau C, Nielsen M, Sheaff M, Steele J, et al. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. Eur J Hum Genet. 2023 Nov;31(11):1261-1269. doi: 10.1038/s41431-023-01448-z. DOI: https://doi.org/10.1038/s41431-023-01448-z
[21] Zocchi L, Lontano A, Merli M, Dika E, Nagore E, Quaglino P, et al. Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management. J Clin Med. 2021;10(16) :3760. doi: 10.3390/jcm10163760. DOI: https://doi.org/10.3390/jcm10163760
[22] Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Jan;36(1):10-30. doi: 10.1016/j.annonc.2024.11.006. DOI: https://doi.org/10.1016/j.annonc.2024.11.006
[23] Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024. J Natl Compr Canc Netw. 2024 Jul;22(5):290-298. doi: 10.6004/jnccn.2024.0036. DOI: https://doi.org/10.6004/jnccn.2024.0036
[24] Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276-92. doi: 10.1200/JCO.2005.10.042. DOI: https://doi.org/10.1200/JCO.2005.10.042
[25] Bennett RL, French KS, Resta RG, Doyle DL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns. 2008;17(5):424-33. doi: 10.1007/s10897-008-9169-9. DOI: https://doi.org/10.1007/s10897-008-9169-9
[26] Geilswijk M, Genuardi M, Woodward ER, Nightingale K, Huber J, Madsen MG, et al. ERN GENTURIS clinical practice guidelines for the diagnosis, surveillance and management of people with Birt-Hogg-Dube syndrome. Eur J Hum Genet. 2024 Dec;32(12):1542-50. doi: 10.1038/s41431-024-01671-2. DOI: https://doi.org/10.1038/s41431-024-01671-2
[27] Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 Aug;23(8):1506-13. doi: 10.1038/s41436-021-01170-5. DOI: https://doi.org/10.1038/s41436-021-01170-5
[28] Sandru F, Petca A, Dumitrascu MC, Petca RC, Carsote M. Peutz-Jeghers syndrome: Skin manifestations and endocrine anomalies (Review). Exp Ther Med. 2021;22(6):1387. doi: 10.3892/etm.2021.10823. DOI: https://doi.org/10.3892/etm.2021.10823
[29] Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N; PHTS Guideline Development Group; European Reference Network GENTURIS. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet. 2020 Oct;28(10):1387-93. doi: 10.1038/s41431-020-0651-7. DOI: https://doi.org/10.1038/s41431-020-0651-7
[30] Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333-51. doi: 10.1038/nrg.2016.49. DOI: https://doi.org/10.1038/nrg.2016.49
[31] Sokolenko AP, Suspitsin EN, Kuligina E, Bizin IV, Frishman D, Imyanitov EN. Identification of novel hereditary cancer genes by whole exome sequencing. Cancer Lett. 2015;369(2):274-88. doi: 10.1016/j.canlet.2015.09.014. DOI: https://doi.org/10.1016/j.canlet.2015.09.014
[32] Telenti A, Pierce LC, Biggs WH, di Iulio J, Wong EH, Fabani MM, et al. Deep sequencing of 10,000 human genomes. Proc Natl Acad Sci U S A. 2016;113(42):11901-6. doi: 10.1073/pnas.1613365113. DOI: https://doi.org/10.1073/pnas.1613365113
[33] Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22(2):245-57. doi: 10.1038/s41436-019-0686-8. DOI: https://doi.org/10.1038/s41436-019-0686-8
[34] Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66(15):7810-7. doi: 10.1158/0008-5472.CAN-06-1114. DOI: https://doi.org/10.1158/0008-5472.CAN-06-1114
[35] Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21(2):151-61. doi: 10.1007/s10897-011-9462-x. DOI: https://doi.org/10.1007/s10897-011-9462-x
[36] Singer CF, Balmana J, Burki N, Delaloge S, Filieri ME, Gerdes AM, et al. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. Eur J Cancer. 2019;106:54-60. doi: 10.1016/j.ejca.2018.10.007. DOI: https://doi.org/10.1016/j.ejca.2018.10.007
[37] Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, et al. Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. Public Health Genomics. 2018;21(3-4):121-32. doi: 10.1159/000496495. DOI: https://doi.org/10.1159/000496495
[38] Perez L, Dioun S, Primiano M, Blank SV, Lipkin S, Ahsan MD, et al. Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening. Cancer. 2024;130(24):4213-20. doi: 10.1002/cncr.35480. DOI: https://doi.org/10.1002/cncr.35480
[39] Usher-Smith JA, Hindmarch S, French DP, Tischkowitz M, Moorthie S, Walter FM, et al. Proactive breast cancer risk assessment in primary care: a review based on the principles of screening. Br J Cancer. 2023;128(9):1636-46. doi: 10.1038/s41416-023-02145-w. DOI: https://doi.org/10.1038/s41416-023-02145-w
[40] de Wert G, Dondorp W, Clarke A, Dequeker EMC, Cordier C, Deans Z, et al. Opportunistic genomic screening. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2021 Mar;29(3):365-377. doi: 10.1038/s41431-020-00758-w. DOI: https://doi.org/10.1038/s41431-020-00758-w
[41] Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023 Mar;34(3):215-227. doi: 10.1016/j.annonc.2022.12.003. DOI: https://doi.org/10.1016/j.annonc.2022.12.003
[42] Parker M, Lucassen A. Concern for families and individuals in clinical genetics. J Med Ethics. 2003;29(2):70-3. doi: 10.1136/jme.29.2.70. DOI: https://doi.org/10.1136/jme.29.2.70
[43] van der Schoot V, van der Meer E, Hillen MA, Yntema HG, Brunner HG, Oerlemans AJM. Exploring uncertainties regarding unsolicited findings in genetic testing. Patient Educ Couns. 2024;119:108064. doi: 10.1016/j.pec.2023.108064. DOI: https://doi.org/10.1016/j.pec.2023.108064
[44] Borry P. Conference Scene: Direct-to-consumer genetic testing in the age of personalized medicine. Per Med. 2009;6(6):617-9. doi: 10.2217/pme.09.61. DOI: https://doi.org/10.2217/pme.09.61
[45] Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: psychological aspects and implications. J Consult Clin Psychol. 2002;70(3):784-97. doi: 10.1037//0022-006x.70.3.784. DOI: https://doi.org/10.1037//0022-006X.70.3.784
